Advertisement
HAE vs SRTS
Which Stock Would AI Choose? Haemonetics Corporation (HAE) vs. Sensus Healthcare (SRTS) Stock Comparison
Key Takeaways
- Haemonetics (HAE) has shown strong relative momentum in recent months, supported by a plasma-collection supply agreement expansion with CSL Plasma and a series of regulatory approvals.
- Sensus Healthcare (SRTS) is a much smaller, earlier-stage medical device company whose shares have been pressured by sharply lower revenue and wider losses in recent quarters.
- HAE offers a larger scale, more diversified revenue base, and improving profitability, while SRTS carries a higher-risk, catalyst-driven profile tied to reimbursement-code adoption and unit sales.
- Tickeron AI Verdict: Based on trend consistency, stability, and recent catalysts, Tickeron's AI would currently favor HAE over SRTS.
- For additional coverage of these names, explore HAE Major News and HAE Today's Price Move, along with SRTS Major News and SRTS Today's Price Move.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating healthcare names often weigh the stability of an established medical technology franchise against the upside potential of a smaller, catalyst-driven device company. This stock comparison examines Haemonetics Corporation (HAE), a global leader in blood and plasma collection technology, against Sensus Healthcare (SRTS), a developer of superficial radiation therapy (SRT) devices for non-melanoma skin cancer. Although both operate in medical devices, their scale, growth profiles, and risk characteristics differ markedly. The comparison is most relevant to traders and investors assessing relative performance, market positioning, and how momentum and fundamentals interact in the current environment.
HAE Overview and Recent Performance
Haemonetics (HAE) develops blood and plasma collection, processing, and hospital patient-care solutions, with its Plasma and Blood Management Technologies businesses serving as core growth platforms. Recent market activity has been notably positive, with the shares advancing strongly over the past several months and reaching new 52-week highs.
Two developments have shaped sentiment. First, CSL Plasma announced plans to complete deployment of Haemonetics' NexSys PCS devices and disposables across all existing U.S. plasma collection centers by the end of 2027, a meaningful expansion of a previously announced, non-exclusive supply agreement. Second, the company has received U.S. Food and Drug Administration (FDA) clearance for products including the Persona PLUS plasma technology and the PerQseal Elite vascular closure system. In its latest reported quarter, revenue rose while adjusted gross margin expanded for the full fiscal year, even as the Interventional Technologies segment remained a soft spot.
SRTS Overview and Recent Performance
Sensus Healthcare (SRTS) manufactures and sells superficial radiation therapy systems, including the SRT-100 portfolio, which offer a non-invasive alternative to surgery for treating non-melanoma skin cancers and keloids. The company is far smaller, with a market capitalization measured in the tens of millions of dollars, and its stock has traded near the lower end of its 52-week range in recent weeks.
Recent performance has been pressured by weak financial results. In its most recent reported quarter, revenue declined sharply year over year, reflecting the delayed recognition of several unit sales tied to third-party financing approvals, while the company posted a wider net loss. Positively, dedicated Current Procedural Terminology (CPT) reimbursement codes for superficial radiotherapy took effect in early 2026, which management views as a catalyst for adoption. Analysts have maintained buy ratings, but several lowered their price targets following the quarterly results, reflecting a recovery narrative that remains unproven.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that monitor thousands of different tickers, each built around distinct trading styles, strategies, timeframes, performance metrics, and sets of securities. Because not every bot suits every market condition, Tickeron curates a focused Trending AI Robots section highlighting the systems currently best aligned with prevailing conditions. The page lets traders browse bots by performance, style, and watchlist coverage, offering a practical way to see how AI-driven strategies are positioning in real time. If you are interested in how automated systems are approaching names like HAE and SRTS, the Trending AI Robots page is a useful starting point.
Head-to-Head Comparison
The two companies sit at opposite ends of the healthcare-device spectrum. Haemonetics benefits from scale, a diversified portfolio across plasma, blood center, and hospital segments, and improving cash generation, giving it a more durable earnings base. Its primary risks include concentration around major plasma customers and continued softness in interventional technologies. Sensus Healthcare, by contrast, is a growth-oriented story dependent on reimbursement-code adoption, financing availability, and unit-selling momentum. Its risk profile is higher, with negative earnings and revenue volatility, though its small size and analyst price targets imply substantial potential upside if catalysts materialize. In terms of market positioning, HAE reflects established momentum and profitability, while SRTS represents a higher-risk, higher-variance opportunity.
Tickeron AI Verdict
Weighing trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor Haemonetics (HAE) in the current environment. The stock combines sustained positive price momentum, expanding profitability, and concrete catalysts such as the CSL Plasma rollout and recent FDA clearances. Sensus Healthcare offers a compelling but less established catalyst path, with recent financial weakness and higher volatility. Accordingly, the AI verdict tilts toward HAE on a risk-adjusted, trend-based basis, while acknowledging that SRTS retains meaningful upside potential should its reimbursement and sales catalysts accelerate.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HAE is a StrongBuy and SRTS is a Hold.
Aroon Indicator for HAE shows an upward move is likely
HAE's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator showed a similar pattern. In 162 of the 212 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on HAE as a result. In 53 of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in 233 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for HAE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 29 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Moving Average Convergence Divergence Histogram (MACD) for HAE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 23 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
HAE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.518) is normal, around the industry mean (4.142). P/E Ratio (57.659) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.676) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (40.124).
SRTS in downward trend: price may decline as a result of having broken its higher Bollinger Band on November 03, 2026
SRTS broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 45 similar instances where the stock broke above the upper band. In 41 of the 45 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SRTS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SRTS as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SRTS just turned positive on November 03, 2026. Looking at past instances where SRTS's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
SRTS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SRTS crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +7.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 222 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (4.142). P/E Ratio (-3.043) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SRTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
HAE | SRTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 96 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 44 | 100 | |
SMR RATING 1..100 | 66 | 97 | |
PRICE GROWTH RATING 1..100 | 35 | 50 | |
P/E GROWTH RATING 1..100 | 4 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRTS's Valuation (27) in the Medical Specialties industry is somewhat better than the same rating for HAE (88). This means that SRTS’s stock grew somewhat faster than HAE’s over the last 12 months.
HAE's Profit vs Risk Rating (44) in the Medical Specialties industry is somewhat better than the same rating for SRTS (100). This means that HAE’s stock grew somewhat faster than SRTS’s over the last 12 months.
HAE's SMR Rating (66) in the Medical Specialties industry is in the same range as SRTS (97). This means that HAE’s stock grew similarly to SRTS’s over the last 12 months.
HAE's Price Growth Rating (35) in the Medical Specialties industry is in the same range as SRTS (50). This means that HAE’s stock grew similarly to SRTS’s over the last 12 months.
HAE's P/E Growth Rating (4) in the Medical Specialties industry is in the same range as SRTS (34). This means that HAE’s stock grew similarly to SRTS’s over the last 12 months.
| HAE | SRTS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 56% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 81% |
| Advances ODDS (%) | 8 days ago 69% | 1 day ago 81% |
| Declines ODDS (%) | 3 days ago 64% | 6 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HAE’s FA Score shows that 1 FA rating(s) are green while SRTS’s FA Score has 1 green FA rating(s).
- HAE’s FA Score: 1 green, 4 red.
- SRTS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HAE’s TA Score shows that 4 TA indicator(s) are bullish while SRTS’s TA Score has 5 bullish TA indicator(s).
- HAE’s TA Score: 4 bullish, 4 bearish.
- SRTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
HAE (@Medical/Nursing Services) experienced а +1.73% price change this week, while SRTS (@Medical/Nursing Services) price change was +0.46% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
HAE is expected to report earnings on Feb 11, 2027.
SRTS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
HAE and
Correlation & Price change
A.I.dvisor indicates that over the last year, HAE has been loosely correlated with SRTS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HAE jumps, then SRTS could also see price increases.
| Ticker / NAME | Correlation To HAE | 1D Price Change % | ||
|---|---|---|---|---|
| HAE | 100% | -1.49% | ||
| SRTS - HAE | 44% Loosely correlated | +3.33% | ||
| ECOR - HAE | 43% Loosely correlated | -0.13% | ||
| PEN - HAE | 42% Loosely correlated | +0.08% | ||
| ATR - HAE | 41% Loosely correlated | -0.72% | ||
| GH - HAE | 39% Loosely correlated | -0.37% | ||
More | ||||
SRTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, SRTS has been loosely correlated with LUNG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SRTS jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To SRTS | 1D Price Change % | ||
|---|---|---|---|---|
| SRTS | 100% | +3.33% | ||
| LUNG - SRTS | 57% Loosely correlated | +6.43% | ||
| HAE - SRTS | 45% Loosely correlated | -1.49% | ||
| AORT - SRTS | 34% Loosely correlated | -1.81% | ||
| GMED - SRTS | 32% Poorly correlated | +0.21% | ||
| MTD - SRTS | 28% Poorly correlated | -0.14% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GVLU | 29.78 | 0.13 | +0.45% |
| Gotham 1000 Value ETF (GVLU) | |||
| AHYB | 44.85 | 0.12 | +0.27% |
| American Century Select High Yield ETF (AHYB) | |||
| QIG | 42.67 | 0.04 | +0.09% |
| WisdomTree U.S. Corporate Bond Fund (QIG) | |||
| GJO | 24.60 | N/A | N/A |
| Synthetic Fixed-Income Securities | |||
| IGOV | 40.10 | -0.18 | -0.45% |
| iShares International Treasury Bond ETF (IGOV) | |||